Or Pfizer can just increase the price to the high end valuation, what's $90M USD to Pfizer given the massive revenue potential for acute respiratory diagnosis (children and adult) and chronic respiratory management for Asthma (children and adult) and COPD (adult)......
Or Pfizer can just increase the price to the high end valuation,...
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #